

SAS:gte 4239-61997 233729 11/11/03

**KLARQUIST SPARKMAN, LLP**

16th Floor World Trade Center, 121 S.W. Salmon Street, Portland, Oregon 97204 U.S.A.

PHONE: 503-226-7391 FAX: 503-228-9446

**TO: Office of Initial Patent Examination – Filing Receipt Corrections**

**Fax No.: 703-746-9195**

**Total No. Pages: 5** including this cover sheet

**Message:** Applicants received the attached Corrected Filing Receipt dated December 2, 2002, with an error in the domestic priority data as claimed by applicant. The correct priority information is marked on the attached sheet for easy reference. Also attached as Exhibit A is a copy of the transmittal letter that was filed with this application on February 6, 2002. Page two of the transmittal letter also lists the correct priority information for this application. Please correct the priority data and issue a second Corrected Filing Receipt. If you do not receive all pages or if you have problems receiving transmittal, please call Greg Euteneier at (503) 226-7391.

**In re application of:** Klinman et al.

**Application No.** 10/068,160

**Filed:** February 6, 2002

**Confirmation No.** 9731

**For:** OLIGODEOXYNUCLEOTIDE AND ITS  
USE TO INDUCE AN IMMUNE  
RESPONSE

**Examiner:** Dave Nguyen

**Art Unit:** 1623


**Attorney Reference No.** 4239-61997

**CERTIFICATE OF FACSIMILE**

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being facsimile transmitted to fax number 703-746-9195 on the date shown below.

Agent  
for Applicant(s)

Date Transmitted November 11, 2003

  
Susan Alpert Siegel, Ph.D.

Registration No. 43,121

November 11, 2003

Date

cc: Docketing

THE INFORMATION CONTAINED IN THIS TRANSMISSION IS CONFIDENTIAL AND ONLY FOR THE INTENDED RECIPIENT IDENTIFIED ABOVE. IF YOU ARE NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION OR USE OF THIS COMMUNICATION IS UNLAWFUL. IF YOU HAVE RECEIVED THIS TRANSMISSION IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE (COLLECT), RETURN THE ORIGINAL MESSAGE TO US, AND RETAIN NO COPY.



NII/SAS/nms

Commissioner for Patents  
Washington, DC 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/068,160	02/06/2002	1632	1572	4239-61997	7	59	1

KLARQUIST SPARKMAN, LLP  
One World Trade Center  
Suite 1600  
121 S.W. Salmon Street  
Portland, OR 97204

CONFIRMATION NO. 9731

CORRECTED FILING RECEIPT



\*OC000000009181498\*

Date Mailed: 12/02/2002

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Applicant(s)**

Dennis Klinman, Potomac, MD;  
Daniela Verthelyi, Potomac, MD;  
Ken Ishii, Rockville, MD;  
James J. Mond, Silver Spring, MD;  
Mayda Gursel, Rockville, MD;

**Assignment For Published Patent Application**

The Govt. of the USA as represented by the Secretary of the Dept of Health and Human Services;

**Domestic Priority data as claimed by applicant**

~~This application is a CIP of 09/958,713  
which claims benefit of 60/128,898 04/12/1999~~

← This application is a CIP of 09/958,713 filed 10/7/02  
which is a 371 of PCT/US00/09839 filed 4/12/00  
which claims benefit of 60/128,898 filed 4/12/99

**Foreign Applications**

If Required, Foreign Filing License Granted: 03/11/2002

Projected Publication Date: 08/29/2002

Non-Publication Request: No

Early Publication Request: No

**Title**

Oligodeoxynucleotide and its use to induce an immune response

**Preliminary Class**

514

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

SAS:jam 02/06/02 97610  
 Attorney Reference Number 4239-61997  
 PATENT

EXPRESS MAIL LABEL NO. EV053213585US  
 DATE OF DEPOSIT: February 6, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION  
 COMMISSIONER FOR PATENTS  
 WASHINGTON, D.C. 20231

Transmitted herewith for filing is the continuing patent application of:

Inventor(s): Dennis M. Klinman, Daniela Verthelyi, Ken Ishii, James J. Mond, Mayda Gursel

For: OLIGODEOXYNUCLEOTIDE AND ITS USE TO INDUCE AN IMMUNE RESPONSE

Enclosed are:


- ☒ 65 pages of specification, 7 pages of claims, and an abstract  
☒ 7 sheet(s) of drawings  
☒ 3 pages of an Oath or Declaration (unsigned)  
☐ Newly executed (original or copy)  
☐ A copy of oath or declaration filed with the prior application (37 C.F.R. § 1.63(d))  
☐ The inventors to be deleted are set forth on a separate sheet attached hereto
- ☒ Nucleotide and/or Amino Acid Sequence Submission  
☒ Computer Readable Copy  
☒ Paper Copy (identical to computer copy), 31 pages  
☒ Statement in compliance with 37 C.F.R. § 1.821 verifying identity of above copies
- ☐ Other:
- Continuing Application:  
☐ Continuation  
☐ Divisional  
☒ Continuation-in-part (CIP)

Information from Prior Application:

Prior Application Number: 09/958,713  
 Examiner: Not yet assigned  
 Art Unit: Not yet assigned

FILING FEE					
For	Claims Filed	Number allotted	Number Extra	Rate	Basic Fee
Total Claims	59	20	= 39	\$18.00	\$ 702.00
Independent Claims	1	3	= 0	\$84.00	\$ 0.00
Multiple Dependent Claim Fee				\$280.00	
TOTAL FILING FEE					\$1442.00

- ☒ A check in the amount of \$1,442.00 to cover ☒ filing fee and ☐ assignment recordal fee is enclosed.



EV053213585US

TRANSMITTAL - Page 1 of 2

SASjam 02/06/02 97610  
Attorney Reference Number 4239-61997  
PATENT

EXPRESS MAIL LABEL NO. EV053213585US  
DATE OF DEPOSIT: February 6, 2002

☒ Assignee for this application is or will be The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services, and applicants request that this information be listed on the published application.

☒ This is a continuation-in-part of U.S. Application No. 09/958,713 filed on October 11, 2001, which claims the benefit of PCT Application No. PCT/US00/09839 filed on April 12, 2000, which claims priority to U.S. Provisional Patent Application No. 60/128,898 filed on April 12, 1999, all of which are incorporated herein by reference in their entirety

☐ Please charge our Deposit Account No. 02-4550 in the amount of \_\_\_\_\_. Two copies of this sheet are enclosed.


☒ The Director is hereby authorized to charge any additional fees which may be required in connection with the filing of this application and recording any assignment filed herewith, or credit over-payment, to Account No. 02-4550. A copy of this sheet is enclosed.

☒ Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

  
Susan Alpert Siegel, Ph.D.  
Registration No. 43,121

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446

cc: Docketing

TRANSMITTAL - Page 2 of 2